Phase 3 Colorectal Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with a type of bowel cancer called adenocarcinoma, located on the left side of the colon or rectum, and the cancer cannot be removed by surgery or has spread to other parts of the body
- Your tumour has been tested and does not have changes (mutations) in genes called KRAS, NRAS, or BRAF — these are sometimes called "wild-type" results
- You are willing to provide a fresh tumour tissue sample (biopsy) for the study
- Your cancer can be measured using standard medical scans, following specific guidelines called RECIST v1.1
- You have not yet received any treatment (such as chemotherapy) for cancer that has spread or cannot be removed — though previous treatment given before or after surgery for earlier-stage cancer is allowed, as long as it finished more than 12 months before the cancer came back or spread
- You are in good enough general health to carry out daily activities with little or no limitation (this is measured on a standard scale called ECOG performance status 0 or 1)
Who may not be able to join:
- You have a history of, or currently have, a lung condition involving scarring or inflammation of the lung tissue (such as interstitial lung disease, pneumonitis, or pulmonary fibrosis), or this cannot be ruled out based on scans done at the start of the study
- You have a known allergy or serious reaction to any of the study drugs or their ingredients, including amivantamab, cetuximab, or the chemotherapy combinations called mFOLFOX6 or FOLFIRI
- You have, or have previously had, another type of cancer that could affect the results of this study or interfere with your safety during treatment (confirm with trial site)
- Your tumour has been found to have a specific feature related to how cells repair DNA, known as mismatch repair deficiency (dMMR) or high microsatellite instability (MSI-H), or your tumour tests positive for a protein called HER2
- You have previously been treated with any therapy that targets specific proteins involved in cancer growth, known as EGFR, MET, or VEGF
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Phone: 844-434-4210
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Progression-Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.